136 related articles for article (PubMed ID: 31577941)
61. LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma LIN28B Control of EWS-FLI1 Stability.
Keskin T; Bakaric A; Waszyk P; Boulay G; Torsello M; Cornaz-Buros S; Chevalier N; Geiser T; Martin P; Volorio A; Iyer S; Kulkarni A; Letovanec I; Cherix S; Cote GM; Choy E; Digklia A; Montemurro M; Chebib I; Nielsen PG; Carcaboso AM; Mora J; Renella R; Suvà ML; Fusco C; Provero P; Rivera MN; Riggi N; Stamenkovic I
Cell Rep; 2020 Mar; 30(13):4567-4583.e5. PubMed ID: 32234488
[TBL] [Abstract][Full Text] [Related]
62. EWSR1-FLI1 Activation of the Cancer/Testis Antigen FATE1 Promotes Ewing Sarcoma Survival.
Gallegos ZR; Taus P; Gibbs ZA; McGlynn K; Gomez NC; Davis I; Whitehurst AW
Mol Cell Biol; 2019 Jul; 39(14):. PubMed ID: 31036566
[TBL] [Abstract][Full Text] [Related]
63. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.
Hahm KB; Cho K; Lee C; Im YH; Chang J; Choi SG; Sorensen PH; Thiele CJ; Kim SJ
Nat Genet; 1999 Oct; 23(2):222-7. PubMed ID: 10508522
[TBL] [Abstract][Full Text] [Related]
64. Induction of tenascin-C by tumor-specific EWS-ETS fusion genes.
Watanabe G; Nishimori H; Irifune H; Sasaki Y; Ishida S; Zembutsu H; Tanaka T; Kawaguchi S; Wada T; Hata J; Kusakabe M; Yoshida K; Nakamura Y; Tokino T
Genes Chromosomes Cancer; 2003 Mar; 36(3):224-32. PubMed ID: 12557222
[TBL] [Abstract][Full Text] [Related]
65. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
66. Prospective Clinical Genomic Profiling of Ewing Sarcoma:
Ogura K; Elkrief A; Bowman AS; Koche RP; de Stanchina E; Benayed R; Mauguen A; Mattar MS; Khodos I; Meyers PA; Healey JH; Tap WD; Hameed M; Zehir A; Shukla N; Sawyers C; Bose R; Slotkin E; Ladanyi M
JCO Precis Oncol; 2022 Aug; 6():e2200048. PubMed ID: 35952322
[TBL] [Abstract][Full Text] [Related]
67. The GR-PDK4 Axis of Evil: Hijacking a Stress SOS to Drive Metastasis.
Chakraborty AA; Keri RA
Endocrinology; 2023 Jun; 164(8):. PubMed ID: 37459450
[No Abstract] [Full Text] [Related]
68. Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical.
Kong Y; Jiang C; Wei G; Sun K; Wang R; Qiu T
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375228
[TBL] [Abstract][Full Text] [Related]
69. Single-cell manifold-preserving feature selection for detecting rare cell populations.
Liang S; Mohanty V; Dou J; Miao Q; Huang Y; Müftüoğlu M; Ding L; Peng W; Chen K
Nat Comput Sci; 2021 May; 1(5):374-384. PubMed ID: 36969355
[TBL] [Abstract][Full Text] [Related]
70. IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy.
Romaniello D; Gelfo V; Pagano F; Sgarzi M; Morselli A; Girone C; Filippini DM; D'Uva G; Lauriola M
Front Cell Dev Biol; 2022; 10():1083743. PubMed ID: 36712972
[TBL] [Abstract][Full Text] [Related]
71. Regulation of EWSR1-FLI1 Function by Post-Transcriptional and Post-Translational Modifications.
Yu L; Davis IJ; Liu P
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672331
[TBL] [Abstract][Full Text] [Related]
72. Input integration by the circadian clock exhibits nonadditivity and fold-change detection.
Manella G; Bolshette N; Golik M; Asher G
Proc Natl Acad Sci U S A; 2022 Nov; 119(44):e2209933119. PubMed ID: 36279450
[TBL] [Abstract][Full Text] [Related]
73. Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors.
Nataraj NB; Noronha A; Lee JS; Ghosh S; Mohan Raju HR; Sekar A; Zuckerman B; Lindzen M; Tarcitano E; Srivastava S; Selitrennik M; Livneh I; Drago-Garcia D; Rueda O; Caldas C; Lev S; Geiger T; Ciechanover A; Ulitsky I; Seger R; Ruppin E; Yarden Y
Cell Rep; 2022 Feb; 38(8):110418. PubMed ID: 35196484
[TBL] [Abstract][Full Text] [Related]
74. TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis.
Uribe ML; Dahlhoff M; Batra RN; Nataraj NB; Haga Y; Drago-Garcia D; Marrocco I; Sekar A; Ghosh S; Vaknin I; Lebon S; Kramarski L; Tsutsumi Y; Choi I; Rueda OM; Caldas C; Yarden Y
Sci Signal; 2021 Jun; 14(688):. PubMed ID: 34158398
[TBL] [Abstract][Full Text] [Related]
75. YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells.
Bierbaumer L; Katschnig AM; Radic-Sarikas B; Kauer MO; Petro JA; Högler S; Gurnhofer E; Pedot G; Schäfer BW; Schwentner R; Mühlbacher K; Kromp F; Aryee DNT; Kenner L; Uren A; Kovar H
Oncogenesis; 2021 Jan; 10(1):2. PubMed ID: 33419969
[TBL] [Abstract][Full Text] [Related]
76. ETV4 Is Necessary for Estrogen Signaling and Growth in Endometrial Cancer Cells.
Rodriguez AC; Vahrenkamp JM; Berrett KC; Clark KA; Guillen KP; Scherer SD; Yang CH; Welm BE; Janát-Amsbury MM; Graves BJ; Gertz J
Cancer Res; 2020 Mar; 80(6):1234-1245. PubMed ID: 32046982
[TBL] [Abstract][Full Text] [Related]
77. ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma.
Srivastava S; Nataraj NB; Sekar A; Ghosh S; Bornstein C; Drago-Garcia D; Roth L; Romaniello D; Marrocco I; David E; Gilad Y; Lauriola M; Rotkopf R; Kimchi A; Haga Y; Tsutsumi Y; Mirabeau O; Surdez D; Zinovyev A; Delattre O; Kovar H; Amit I; Yarden Y
Cell Rep; 2019 Oct; 29(1):104-117.e4. PubMed ID: 31577941
[TBL] [Abstract][Full Text] [Related]
78. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
[TBL] [Abstract][Full Text] [Related]
79. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
80. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
